• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors.

作者信息

Nandakumar Vijayalakshmi, Mills John R

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

出版信息

Clin Chem. 2019 Feb 1;65(2):357. doi: 10.1373/clinchem.2018.295097.

DOI:10.1373/clinchem.2018.295097
PMID:32100826
Abstract
摘要

相似文献

1
The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors.肿瘤突变负荷作为免疫检查点抑制剂反应预测指标的现状与未来
Clin Chem. 2019 Feb 1;65(2):357. doi: 10.1373/clinchem.2018.295097.
2
Tumor mutational burden.肿瘤突变负荷
Cancer Cytopathol. 2019 Dec;127(12):735-736. doi: 10.1002/cncy.22174. Epub 2019 Aug 21.
3
Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies.癌症突变负荷：免疫检查点阻断疗法中越多越好。
EBioMedicine. 2016 Nov;13:1-2. doi: 10.1016/j.ebiom.2016.11.014. Epub 2016 Nov 11.
4
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
5
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.DNA 损伤反应通路中的突变可作为免疫检查点阻断的潜在生物标志物。
Cancer Res. 2018 Nov 15;78(22):6486-6496. doi: 10.1158/0008-5472.CAN-18-1814. Epub 2018 Aug 31.
6
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.TCGA癌症中非同义突变的负担及候选免疫检查点抑制剂反应
Cancer Res. 2016 Jul 1;76(13):3767-72. doi: 10.1158/0008-5472.CAN-16-0170. Epub 2016 May 18.
7
Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.肿瘤突变负荷与肿瘤负担比及其对 PD-1/PD-L1 免疫治疗临床获益的预测。
Med Hypotheses. 2018 Jul;116:111-113. doi: 10.1016/j.mehy.2018.05.005. Epub 2018 May 16.
8
JAMA Oncology Patient Page. The Evolution of a Cancer.《美国医学会杂志·肿瘤学》患者专页。癌症的演变
JAMA Oncol. 2015 Sep;1(6):850. doi: 10.1001/jamaoncol.2015.2199.
9
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.预测 PD-1/PD-L1 抑制剂疗效的生物标志物。
Mol Cancer. 2018 Aug 23;17(1):129. doi: 10.1186/s12943-018-0864-3.
10
[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].[癌症治疗中检查点阻断抑制剂疗效的预测生物标志物]
Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26.

引用本文的文献

1
Exploring the genetic profiles linked to senescence in thyroid tumors: insights on predicting disease progression and immune responses.探索甲状腺肿瘤中与衰老相关的基因谱：对预测疾病进展和免疫反应的见解。
Front Oncol. 2025 Feb 6;15:1545656. doi: 10.3389/fonc.2025.1545656. eCollection 2025.
2
Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach.铜死亡相关 lncRNA 特征在 LUAD 预后和免疫治疗中的意义：一种机器学习方法。
Thorac Cancer. 2023 Jun;14(16):1451-1466. doi: 10.1111/1759-7714.14888. Epub 2023 Apr 19.
3
A Novel Pyroptosis-Related Gene Signature for Prediction of Disease-Free Survival in Papillary Thyroid Carcinoma.
一种用于预测甲状腺乳头状癌无病生存期的新型焦亡相关基因特征
J Pers Med. 2022 Dec 29;13(1):85. doi: 10.3390/jpm13010085.
4
High tumor mutation burden indicates better prognosis in colorectal cancer patients with mutations.高肿瘤突变负荷表明携带突变的结直肠癌患者预后较好。
Front Oncol. 2022 Nov 14;12:1015308. doi: 10.3389/fonc.2022.1015308. eCollection 2022.
5
MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.基于 miRNA 的子宫内膜癌肿瘤突变负担诊断和预后预测模型。
Bioengineered. 2021 Dec;12(1):3603-3620. doi: 10.1080/21655979.2021.1947940.
6
Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.肿瘤突变负荷通过基因和免疫微环境变化预测甲状腺乳头状癌复发
Front Endocrinol (Lausanne). 2021 Jun 23;12:674616. doi: 10.3389/fendo.2021.674616. eCollection 2021.
7
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.三阴性乳腺癌的肿瘤突变负担和免疫浸润特征：全基因组高通量数据分析。
Front Immunol. 2021 Apr 21;12:650491. doi: 10.3389/fimmu.2021.650491. eCollection 2021.
8
Immunotherapy and predictive immunologic profile: the tip of the iceberg.免疫治疗和预测性免疫特征：冰山一角。
Med Oncol. 2021 Mar 31;38(5):51. doi: 10.1007/s12032-021-01497-8.
9
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.肿瘤突变评分比肿瘤突变负担在预测非小细胞肺癌免疫治疗反应方面更具优势。
Cancer Immunol Immunother. 2021 Aug;70(8):2367-2378. doi: 10.1007/s00262-021-02868-w. Epub 2021 Feb 3.
10
Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer.免疫细胞溶解活性作为前列腺癌免疫检查点抑制剂治疗的指标
Front Bioeng Biotechnol. 2020 Aug 6;8:930. doi: 10.3389/fbioe.2020.00930. eCollection 2020.